CoChat

A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented Candida or Aspergillus Infections in Pediatric Patients

Zaoutis, Theoklis E., Jafri, Hasan S., Huang, Li-Min, Locatelli, Franco, Barzilai, Asher, Ebell, Wolfram, Steinbach, William J., Bradley, John, Lieberman, Jay M., Hsiao, Chih-Cheng, Seibel, Nita, Laws, Hans-Juergen, Gamba, Melinda, Petrecz, Maria, Taylor, Arlene F., Strohmaier, Kim M., Chow, Joseph W., Kartsonis, Nicholas A., Ngai, Angela L. · 2009 · Pediatrics
Cited by 108

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

OBJECTIVE. We evaluated the safety, tolerability, and efficacy of caspofungin in pediatric patients with invasive aspergillosis, invasive candidiasis, or esophageal candidiasis. METHODS. This was a multicenter, prospective, open-label study in children 3 months to 17 years of age with proven or probable invasive aspergillosis, proven invasive candidiasis, or proven esophageal candidiasis. All of the patients received caspofungin 70 mg/m2 on day 1, followed by 50 mg/m2 per day (maximum: 70 mg/day), as primary or salvage monotherapy. Favorable response was defined as complete resolution of clinical findings and microbiologic (or radiographic/endoscopic) eradication (complete response) or significant improvement in these parameters (partial response). Efficacy was assessed at the end of caspofungin therapy in patients with a confirmed diagnosis who received ≥1 dose of caspofungin. The primary safety evaluation was the proportion of patients with clinical or laboratory drug-related adverse events. RESULTS. Of the 49 patients enrolled, 3 were <2 years of age, 30 were 2 to 11 years of age, and 16 were 12 to 17 years of age. Forty-eight patients had confirmed disease: invasive aspergillosis (10), invasive candidiasis (37), and esophageal candidiasis (1). Eight of 10 patients with invasive aspergillosis had pulmonary involvement; 34 of 37 patients with invasive candidiasis had candidemia. Caspofungin was given for 2 to 87 days. Success at end of therapy was achieved in 5 of 10 patients with invasive aspergillosis, 30 of 37 with invasive candidiasis, and 1 of 1 with esophageal candidiasis. One patient (invasive candidiasis) relapsed during the 28-day follow-up period. Drug-related clinical or laboratory adverse events occurred in 27% and 35% of patients, respectively. There were no serious drug-related adverse events or discontinuations of caspofungin because of toxicity. CONCLUSIONS. Caspofungin was generally well tolerated in pediatric patients aged 6 months through 17 years. Efficacy outcomes in patients with invasive aspergillosis or invasive candidiasis were consistent with previous adult studies in these indications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1542/peds.2008-1158

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 108

Metadata

Authors
Zaoutis, T. E., Jafri, H. S., Huang, L.-M., Locatelli, F., Barzilai, A., Ebell, W., Steinbach, W. J., Bradley, J., Lieberman, J. M., Hsiao, C.-C., Seibel, N., Laws, H.-J., Gamba, M., Petrecz, M., Taylor, A. F., Strohmaier, K. M., Chow, J. W., Kartsonis, N. A., & Ngai, A. L.
Venue
Pediatrics
Published
2009-03-01
Volume
123
Issue
3
Pages
877-884
ISSN
  • 0031-4005 (ISSN-L)
  • 1098-4275
OpenAlex
W1994259218
Cited by
108
References
5
FWCI
13.19
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented Candida or Aspergillus Infections in Pediatric Patients. https://app.cochat.ai/papers/10.1542/peds.2008-1158
The paper
Zaoutis, T. E., Jafri, H. S., Huang, L.-M., Locatelli, F., Barzilai, A., Ebell, W., Steinbach, W. J., Bradley, J., Lieberman, J. M., Hsiao, C.-C., Seibel, N., Laws, H.-J., Gamba, M., Petrecz, M., Taylor, A. F., Strohmaier, K. M., Chow, J. W., Kartsonis, N. A., & Ngai, A. L. (2009). A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented Candida or Aspergillus Infections in Pediatric Patients. Pediatrics. https://doi.org/10.1542/peds.2008-1158

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.